Recent news on Vincristine Sulfate

Hana Biosciences Announces First Quarter 2007 Results  -  May 14, 2007
Primenewswire (press release),Led by its Optisome(tm) platform-Marqibo(r), Alocrest(tm), and Optisomal Topotecan, Hana is initiating a Phase 2 trial of Marqibo(r) (vincristine sulfate

Hana Biosciences Provides Pipeline Update  -  Mar 23, 2007
FinanzNachrichten.de,Marqibo ® (vincristine sulfate liposomes injection) - Hana is no longer pursuing a Special Protocol Assessment (SPA) with the US Food and Drug

Hana Biosciences Receives Orphan Drug Designation for Marqibo ...  -  Jan 17, 2007
PipelineReview.com (press release),Today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for Marqibo(R) (vincristine sulfate liposomes injection)

Hana Biosciences Announces Filing of a Special Protocol Assessment ...  -  Dec 20, 2006
PharmaLive.com (press release),...trial for Marqibo(R) (vincristine sulfate liposomes injection) in adults with acute lymphoblastic leukemia (ALL) in second relapse and beyond.

Hana Biosciences Announces Data to be Presented On Talvesta ...  -  Dec 8, 2006
PharmaLive.com (press release),...will present data from the completed Phase I trials for Talvesta(tm) (talotrexin) for Injection and Marqibo(r) (vincristine sulfate liposomes injection)

Hana Biosciences Announces Third Quarter 2006 Results  Nov 2, 2006
Initiated a multicenter Phase II clinical trial of Marqibo(r) (vincristine sulfate liposomes injection) in patients with relapsed or refractory acute ... -PrimeZone (press release), Hana Biosciences Announces Conference Call on Third Quarter 2006 ...  Oct 25, 2006
...update will include a review of Hana’s pipeline including Zensanaâ„¢ (Ondansetron HCI) Oral Spray and Marqibo® (vincristine sulfate liposomes injection). ... -Business Wire (press release), Hana initiates Marqibo phase II trial in relapsed or refractory ...  Sep 11, 2006
...company focused on advancing cancer care, announced the initiation of a multicenter phase II clinical trial of Marqibo (vincristine sulfate liposomes injection ... -Therapeutics Daily (subscription)

Hana Biosciences Announces Data to be Presented On Talvesta ...  -  Dec 8, 2006
PharmaLive.com (press release),...will present data from the completed Phase I trials for Talvesta(tm) (talotrexin) for Injection and Marqibo(r) (vincristine sulfate liposomes injection)

Hana Biosciences Initiates Marqibo(R) Phase II Clinical Trial in ...  Aug 17, 2006
...on advancing cancer care, today announced the initiation of a multi-center Phase II clinical trial of Marqibo(R) (vincristine sulfate liposomes injection) in ... -International News Service

Marqiboâ„¢ Not Approved for NHL  Jun 30, 2006
...that the anti-cancer drug, Marqibo™ (vincristine sulfate liposomes injection) is “not approvable� under their accelerated approvable regulations based on ... -Cancer Consultants



Hana Biosciences Completes Licensing of Three Targeted Cancer Drug ...  May 8, 2006
...-- Hana Plans to Initiate Pivotal Trials for Marqibo(R) (vincristine sulfate) Liposomes Injection in Hematological Malignancies in 2006. ... - Genetic Engineering News

Hana Biosciences Reports First Quarter 2006 Results  May 4, 2006
The three candidates are known as Marqibo(R) (vincristine sulfate) Liposomes Injection, Vinorelbine Liposomes Injection, and Topotecan Liposomes Injection. ... - Genetic Engineering News





Getting the patient's mind off medicine at Packard's Children's ...  Apr 9, 2006
Following surgery and radiation, she now comes in for weekly doses of vincristine sulfate, and chemotherapy every three weeks, all applied through a port in ... - San Francisco Chronicle

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional